Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1788544 | 0.89 | SMYD3 (0.42) | KDM4ESMYD3NAMPTPRMT5TPSAB1 | |
| SCHEMBL1789797 | 0.87 | MEN1 (0.46) | KDM4EKMT2AALDH1A1MEN1NAMPT | |
| SCHEMBL1789721 | 0.86 | MEN1 (0.47) | KDM4EKMT2AALDH1A1MEN1NAMPT | |
| SCHEMBL1789735 | 0.84 | HRH3 (0.48) | KDM4EKMT2AALDH1A1SMYD3LMNA | |
| SCHEMBL1791890 | 0.81 | NAMPT (0.51) | NAMPT | |
| SCHEMBL1787713 | 0.81 | SMYD3 (0.53) | SMYD3NAMPTTPSAB1HDAC6 | |
| SCHEMBL1790107 | 0.81 | NAMPT (0.48) | KDM4ELMNANAMPT | |
| SCHEMBL1788777 | 0.80 | HRH3 (0.46) | BCHEMAOBTPSAB1HDAC6 | |
| SCHEMBL1789863 | 0.79 | SMYD3 (0.38) | SMYD3NAMPTPRMT5HDAC6 | |
| SCHEMBL1787579 | 0.79 | NAMPT (0.49) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2326625-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2011-06-01 | — | — | EP | disclosed |
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| WO-2010007382-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED. (JP) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | HRH4, HRH3, HRH2 | KDM4E 1983/4885KMT2A 731/4885ALDH1A1 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.